Detalles de la búsqueda
1.
Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial.
Rheumatology (Oxford)
; 61(7): 2856-2866, 2022 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34730795
2.
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
Ann Rheum Dis
; 80(3): 312-320, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33272960
3.
An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis.
Rheumatology (Oxford)
; 59(12): 3858-3868, 2020 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32521015
4.
Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study.
Ann Rheum Dis
; 78(6): 754-760, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30902820
5.
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
Lancet
; 390(10102): 1585-1594, 2017 Sep 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-28755782
6.
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.
Ann Rheum Dis
; 77(2): 234-240, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29042358
7.
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.
Ann Rheum Dis
; 76(1): 58-64, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26318384
8.
Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.
Rheumatology (Oxford)
; 56(10): 1771-1779, 2017 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28957563
9.
Effect of treatment with original or biosimilar adalimumab on SARS-CoV2 vaccination antibody titers.
Int J Pharm X
; 7: 100229, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38292298
10.
Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study.
J Bone Miner Res
; 39(3): 202-210, 2024 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38477751
11.
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.
Ann Rheum Dis
; 72(6): 863-9, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22730366
12.
Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis.
Rheumatol Ther
; 9(3): 839-850, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35304684
13.
Clinical effectiveness and safety of intra-articular injection of HYALGO in the management of knee osteoarthritis symptoms: A multicenter prospective study.
J Clin Orthop Trauma
; 19: 75-80, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34099970
14.
Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study.
Arthritis Rheumatol
; 73(1): 110-120, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32770640
15.
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study.
Rheumatol Ther
; 8(2): 903-919, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33913086
16.
Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2).
Rheumatol Ther
; 8(1): 199-217, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33278016
17.
Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study.
BioDrugs
; 34(6): 809-823, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33119861
18.
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study.
ACR Open Rheumatol
; 2(2): 119-127, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31957970
19.
FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension.
Arthritis Res Ther
; 21(1): 281, 2019 12 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31831079
20.
Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study.
Rheumatol Ther
; 5(2): 447-462, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30121827